A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.

@article{Persky2018API,
  title={A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.},
  author={Daniel O Persky and Hong-li Li and Lisa M Rimsza and Paul M Barr and Leslie L Popplewell and Charles L Bane and Ann Von Gehr and Michael L. Leblanc and Richard I. Fisher and Sonali M Smith and Jonathan W. Friedberg},
  journal={American journal of hematology},
  year={2018},
  volume={93 4},
  pages={486-493}
}
Loss of major histocompatibility Class II expression (MHCII) in diffuse large B-cell lymphoma (DLBCL) correlates with decreased survival. MHCII transcription is in part regulated by histone acetylation. We tested the hypothesis that combination of histone deacetylase inhibitor (HDACI) with standard chemotherapy would improve outcomes in DLBCL in part through increased MHCII expression. S0806 was a single arm phase I/II trial of vorinostat given at 400 mg po daily on days 1-9 (subsequently… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 7 times. VIEW TWEETS